This is a working overview of drug affinity complex, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-07-24. Anything still debated is marked as such rather than presented as settled.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
In February 2023, Reuters reported that President Lula would meet with General Secretary of the Chinese Communist Party Xi Jinping during a four-day trip to China on 28 March to hold talks about trade, including green economy, digital inclusion, reindustrialization and the Russia-Ukraine War. On 17 March 2023, Itamaraty confirmed Lula's trip to China, adding that he would also meet with Chinese premier Li Qiang and National People's Congress chairman Zhao Leji. A week later, New Development Bank (NDB), whose headquarters are in Shanghai, elected Brazilian former president Dilma Rousseff as its new CEO after president Lula made his official appointment. On 24 March, however, due to health issues Lula canceled his trip which was later rescheduled for 11–14 April. As part of a separate high-level business forum between Brazilian and Chinese officials and hundreds of business people in Beijing, both countries announced on 29 March they were starting to trade in their own currencies (the Real and the Renmimbi) instead of in the US dollar. In April 2023, President Lula, who was accompanied by many of his cabinet ministers, Brazilian state governors and lawmakers, met with Chinese deputy foreign minister Xie Feng upon their arrival in Shanghai, where Lula also attended Brazilian former president Dilma Rousseff inauguration as the new NDB CEO, visited a Huawei center and spoke with several Chinese chairpeople including BYD CEO Wang Chuanfu and China Communications Construction Company (CCCC) CEO Wang Tongzhou.
==== 2025 ==== Starting in January 2025, WWE began a partnership with Netflix where Raw would broadcast live worldwide weekly. Internationally outside the United States, all episodes of SmackDown and NXT, as well as livestreaming supercards, would also move to Netflix. With this partnership, WWE discontinued the WWE Network in all countries, with the exception of a few due to pre-existing contracts; by April 1, 2026, all other countries had transitioned to Netflix, bringing a complete end to the WWE Network, with the exception of Sub-Saharan Africa and Japan, which remain on SuperSport and Abema, respectively. Every livestreaming supercard in 2025 would air on Peacock in the United States until August 2025, after which, they transferred to ESPN. With the discontinuation of the WWE Network around the world, the "Network exclusive" notation is no longer valid as of January 2025.
== External links == Literature by and about Katja Becker in the German National Library catalogue Curriculum vitae of Katja Becker Archived 2016-04-06 at the Wayback Machine, Chair of Biochemistry and Molecular Biology, Justus Liebig University Katja Becker in the database of renowned academics from AcademiaNet List of Katja Becker's publications Archived 2018-05-10 at the Wayback Machine from the Biochemistry and Molecular Biology group's website Membership in the workgroup "Ethics in Science" Archived 2016-08-19 at the Wayback Machine of the Jungen Akademie Katja Becker publications indexed by Google Scholar
Sources: en.wikipedia.org
codons, resulting in 2078 free parameters. However, the rates for transitions between codons which differ by more than one base are often assumed to be zero, reducing the number of free parameters to only
== Detecting proteins == In some applications, it is necessary to measure the total amount of protein present, rather than the levels of one particular protein. In these cases nonspecific protein assays can be used to quantitate the amount of protein in a sample. Common nonspecific protein assays include the Warburg–Christian method, Kjeldahl method, Lowry assay, and Bradford assay. Many of these rely on the spectrophotometric properties of proteins themselves or in complex with various dyes or reagents. For example, the Bradford Assay exploits the absorbance properties of Coomassie brilliant blue G-250 dye. When free of protein, the dye is red but once bound to protein it turns blue. The Kjeldahl method, in contrast, does not use any dye and is instead a titrimetric assay, sensitive to the nitrogen content in the sample, which correlates with protein content. These assays vary widely in sensitivity, specificity to proteins over other compounds in the sample, and cost.
However, after the Qualifying Final between Collingwood and West Coast was drawn and replayed, Essendon lost to Collingwood in both the second semi-final and the grand final. Following the 1991 season, Essendon moved its home games from its traditional home ground at Windy Hill to the larger and newly renovated MCG. This move generated large increases in game attendances, memberships and revenue for the club. The club's training and administrative base remained at Windy Hill until 2013. Following the retirement of Tim Watson and Simon Madden in the early 1990s, the team was built on new players such as Gavin Wanganeen, Joe Misiti, Mark Mercuri, Michael Long, Dustin Fletcher (son of Ken) and James Hird, who was taken at No. 79 in the 1990 draft. This side became known as the "Baby Bombers", as the core of the 1993 premiership side was made up of young players early in their careers. The team won the 1993 Grand Final against Carlton and that same year, Gavin Wanganeen won the Brownlow Medal, the first awarded to an Essendon player since 1976. Three years later, James Hird was jointly awarded the medal with Michael Voss of Brisbane. In 2000, the club shifted the majority of its home games to the newly opened Docklands Stadium, signing a 25-year deal to play seven home matches per year at the venue, with the other four remaining at the MCG. The season was one of the most successful by any team in VFL/AFL history, and the club opened with 20 consecutive wins before they lost to the Western Bulldogs in round 21.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.